IntrinsicIntrinsic
← All summaries

ARDELYX, INC.

ARDX
Financials & Chart →

Business Summary

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for significant unmet medical needs. The company operates in a single business segment, which encompasses the development and commercialization of biopharmaceutical products. Its primary focus is on therapies derived from tenapanor, a first-in-class, oral, small molecule NHE3 inhibitor. The company has incurred losses in each year since its inception in October 2007, with an accumulated deficit of $946.9 million as of December 31, 2025 .

The core business model revolves around the commercialization of two tenapanor-based therapies: IBSRELA and XPHOZAH, primarily in the U.S., and through collaboration partnerships in certain ex-U.S. territories. Revenue is generated from product sales, product supply to partners, licensing fees, development and regulatory milestones, and sales-based royalties. The company also has a pipeline asset, RDX10531, a next-generation NHE3 inhibitor, in early development.

IBSRELA, a tenapanor-based therapy, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). The company believes IBSRELA can benefit approximately 13 million Americans suffering from IBS-C. Competition for IBSRELA primarily comes from prescription products like Linzess (linaclotide), Trulance (plecanatide), and generic lubiprostone, as well as over-the-counter products. For the fiscal year ended December 31, 2025, IBSRELA generated net product sales of $274.207 million , an increase of 73% from $158.286 million in 2024 .

XPHOZAH, also a tenapanor-based therapy, is approved in the U.S. to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy for patients with an inadequate response or intolerance to phosphate binders. It is estimated that over 550,000 adult CKD patients are on dialysis in the U.S., with approximately 80% treated with phosphate-lowering therapies. XPHOZAH is the first therapy to block phosphate absorption at the primary site of uptake. For the fiscal year ended December 31, 2025, XPHOZAH generated net product sales of $103.601 million , a decrease of 36% from $160.910 million in 2024 . This decrease was primarily due to the loss of Medicare Part D reimbursement for XPHOZAH, effective January 1, 2025, when it became part of the ESRD Prospective Payment System.

Total revenues for the fiscal year ended December 31, 2025, were $407.320 million , an increase of 22% from $333.615 million in 2024 . Product sales, net, accounted for $377.808 million in 2025, up 18% from $319.196 million in 2024 . Product supply revenue increased by 36% to $15.879 million in 2025 from $11.649 million in 2024 . Licensing revenue was $5.088 million in 2025, a significant increase from $0.078 million in 2024 , primarily due to a $5.0 million milestone from Fosun Pharma. Non-cash royalty revenue related to the sale of future royalties was $8.545 million in 2025, up from $2.692 million in 2024 .

Gross profit for 2025 is not explicitly stated, but cost of sales was $39.537 million . Operating expenses included research and development (R&D) of $71.527 million and selling, general and administrative (SG&A) expenses of $337.233 million . This resulted in a loss from operations of $40.977 million . Net loss for the year was $61.599 million , leading to a diluted EPS of $(0.26) . As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $264.689 million , an increase of 5.8% from $250.100 million in 2024 . Total long-term debt was $202.834 million . Net cash used in operating activities was $42.483 million in 2025.

Year-over-year, IBSRELA product sales, net, grew by $115.921 million in 2025, reflecting higher demand and net price. XPHOZAH product sales, net, decreased by $57.309 million in 2025, primarily due to the loss of Medicare Part D reimbursement. Total product sales, net, increased by $58.612 million or 18% in 2025. The gross-to-net (GTN) adjustment percentage increased to 30.2% in 2025 from 25.6% in 2024 , reflecting unfavorable payor mix shifts due to the XPHOZAH Medicare Part D reimbursement change. R&D expenses increased by $19.210 million or 37% in 2025, driven by clinical trial activities and increased headcount. SG&A expenses increased by $78.541 million or 30% in 2025, reflecting higher commercialization and administrative costs.

Significant operational developments during 2025 included the NDA approval for tenapanor in China for hyperphosphatemia in February 2025, triggering a $5.0 million milestone payment . The company initiated ACCEL (ten-03-301), a Phase 3 clinical trial for tenapanor in chronic idiopathic constipation (CIC) in January 2026, with topline data expected in the second half of 2027. A development program for RDX10531, a next-generation NHE3 inhibitor, was announced in October 2025, with an IND submission planned for the second half of 2026. A new patent (U.S. Patent No. 12,539,299) covering the commercial formulations of IBSRELA and XPHOZAH was issued on January 22, 2026, with an expiration date of November 26, 2042.

Business Outlook

The company's principal strategy is to continue commercial momentum with its current products, IBSRELA and XPHOZAH, while advancing and expanding a portfolio of important medicines for patients with unmet medical needs. Key priorities include driving significant IBSRELA growth, maintaining XPHOZAH commercial momentum, further advancing its pipeline and portfolio, and maintaining a solid financial foundation to support future growth. The company expects to increasingly rely on cash generated from commercial operations to fund its operating plan, while maintaining financial flexibility through future equity sales and debt financing.

A major growth area is the expansion of the IBSRELA eligible patient population to include patients with chronic idiopathic constipation (CIC). In January 2026, the company initiated ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of tenapanor for the treatment of CIC. Enrollment in ACCEL is expected throughout 2026, with topline data read out in the second half of 2027. CIC is estimated to affect more than 34 million Americans. If successful, the company intends to submit a supplemental NDA to the FDA for tenapanor for the CIC indication.

Another growth vector is the development of RDX10531, a next-generation NHE3 inhibitor. This development program was announced in October 2025, and the company is currently conducting activities to support an IND submission to the FDA for RDX10531 in the second half of 2026. The company believes RDX10531 has potential application across multiple therapeutic areas.

Operationally, the company anticipates a materially lower pace of revenue growth for XPHOZAH compared to prior expectations due to the elimination of Medicare Part D coverage for XPHOZAH, effective January 1, 2025, and its inclusion in the ESRD Prospective Payment System. The company's strategy for XPHOZAH remains a targeted promotional focus on nephrology healthcare providers to preserve patient access. The company expects to continue expending substantial resources for the foreseeable future, including costs for commercializing IBSRELA and XPHOZAH, conducting pediatric clinical trials for IBSRELA, and funding the Phase 3 clinical trial for tenapanor in CIC and the RDX10531 development program.

Regarding capital allocation, the company has an option to draw an additional $100.0 million of committed senior secured term loans, consisting of two separate term loans, each in a principal amount of $50.0 million . The Term F Loan may be drawn by June 30, 2026 , and the Term G Loan by December 20, 2026 . The company also has an automatic shelf registration statement on Form S-3ASR, filed in November 2025, for the offering and sale of up to $100.0 million of common stock through "at-the-market offerings." The company does not currently intend to pay any cash dividends on its common stock for the foreseeable future, instead planning to invest future earnings to fund business opportunities.

Structural headwinds and execution risks include the uncertainty surrounding the commercial opportunity for XPHOZAH due to its inclusion in the ESRD PPS and the elimination of Medicare Part D coverage. The company also faces risks related to maintaining sufficient market acceptance and securing adequate coverage and reimbursement for both IBSRELA and XPHOZAH. Current and future healthcare reform legislation, regulation, or actions by the current administration, such as the IRA and the One Big Beautiful Bill Act, may increase the difficulty and cost of commercializing approved products and could adversely affect pricing and revenue. The company also relies completely on third-party contract manufacturing organizations (CMOs), including certain single-source suppliers, which poses risks to supply chain and manufacturing capacity.

Risk Factors

The company faces several material risks, including its history of losses and the uncertainty of achieving and sustaining cash flow positivity, particularly if revenue growth for IBSRELA and XPHOZAH does not meet expectations or if significant investments are made in pipeline expansion . A critical risk for XPHOZAH is its inclusion in the ESRD Prospective Payment System as of January 1, 2025, which eliminated Medicare Part D coverage and resulted in a negative and material impact on XPHOZAH revenue in 2025, with expectations of a materially lower pace of revenue growth going forward . The company is substantially dependent on the successful commercialization of IBSRELA and XPHOZAH, and failure to maintain market acceptance, grow market share, or secure adequate coverage and reimbursement could significantly harm its business . Undesirable side effects from either product could limit commercial success, lead to regulatory actions, or result in product liability lawsuits . The company relies completely on third-party CMOs, including single-source suppliers, for manufacturing, and any failure in their compliance, raw material sourcing, or production could materially harm commercialization efforts . The company's operating activities are restricted by covenants in its $300.0 million loan and security agreement with SLR, and an event of default could require immediate repayment of the $200.0 million outstanding indebtedness, which would materially adversely affect the business . Furthermore, current and future healthcare reform legislation, such as the IRA and the One Big Beautiful Bill Act, and actions by the current administration, including potential tariffs and mandatory payment models, may increase commercialization costs, adversely affect product prices, and reduce Medicaid funding, negatively impacting the company's business and results of operations . The company is also exposed to risks related to intellectual property, including the ability to obtain, maintain, and enforce patents, and potential claims of infringement by third parties, which could be costly and time-consuming . Cybersecurity threats, including attacks and data breaches, could compromise sensitive information and expose the company to liability .

Management Priorities

Management emphasizes a commitment to developing and commercializing innovative medicines that address unmet patient needs, with a principal strategy to continue commercial momentum for current products while expanding the portfolio. Strategic priorities include driving significant IBSRELA growth, maintaining XPHOZAH commercial momentum, further advancing the pipeline and portfolio, and maintaining a solid financial foundation. The company expects to increasingly rely on cash generated from commercial operations to fund its operating plan, while maintaining financial flexibility to source cash from future equity sales and debt financing. Management has highlighted the initiation of the ACCEL Phase 3 clinical trial for tenapanor in chronic idiopathic constipation (CIC), with enrollment expected throughout 2026 and topline data in the second half of 2027. Additionally, a development program for RDX10531, a next-generation NHE3 inhibitor, was announced in October 2025, with an IND submission targeted for the second half of 2026. Management also noted the issuance of U.S. Patent No. 12,539,299 on January 22, 2026, covering the commercial formulations of IBSRELA and XPHOZAH, with an expiration date of November 26, 2042.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1A, Risk Factors — Risks Related to our Financial Condition and Capital Requirements
  2. [2] Item 7, MD&A — Product Sales, Net
  3. [3] Item 7, MD&A — Product Sales, Net
  4. [4] Item 7, MD&A — Product Sales, Net
  5. [5] Item 7, MD&A — Product Sales, Net
  6. [6] Item 7, MD&A — Total Revenues
  7. [7] Item 7, MD&A — Total Revenues
  8. [8] Item 7, MD&A — Total Revenues
  9. [9] Item 7, MD&A — Total Revenues
  10. [10] Item 7, MD&A — Total Revenues
  11. [11] Item 7, MD&A — Total Revenues
  12. [12] Item 7, MD&A — Total Revenues
  13. [13] Item 7, MD&A — Total Revenues
  14. [14] Item 7, MD&A — Total Revenues
  15. [15] Item 7, MD&A — Total Revenues
  16. [16] Item 7, MD&A — Total costs and operating expenses
  17. [17] Item 7, MD&A — Total costs and operating expenses
  18. [18] Item 7, MD&A — Total costs and operating expenses
  19. [19] Item 7, MD&A — Loss from operations
  20. [20] Item 7, MD&A — Net loss
  21. [21] Item 7, MD&A — Net loss per share of common stock - basic and diluted
  22. [22] Item 7, MD&A — Total liquid funds
  23. [23] Item 7, MD&A — Total liquid funds
  24. [24] Item 7, MD&A — Total long-term debt
  25. [25] Item 7, MD&A — Net cash used in operating activities
  26. [26] Item 7, MD&A — Product sales, net
  27. [27] Item 7, MD&A — Product sales, net
  28. [28] Item 7, MD&A — Total product sales, net
  29. [29] Item 7, MD&A — GTN adjustment percentage
  30. [30] Item 7, MD&A — GTN adjustment percentage
  31. [31] Item 7, MD&A — Total research and development expenses
  32. [32] Item 7, MD&A — Selling, General and Administrative
  33. [33] Item 7, MD&A — Executive Summary and Financial Highlights
  34. [34] Item 7, MD&A — Sources of Liquidity
  35. [35] Item 7, MD&A — Sources of Liquidity
  36. [36] Item 7, MD&A — Sources of Liquidity
  37. [37] Item 7, MD&A — Sources of Liquidity
  38. [38] Item 7, MD&A — Sources of Liquidity
  39. [39] Item 1A, Risk Factors — XPHOZAH became part of the ESRD PPS on January 1, 2025...
  40. [40] Item 1A, Risk Factors — We are substantially dependent on the successful commercialization of IBSRELA...
  41. [41] Item 1A, Risk Factors — IBSRELA and/or XPHOZAH may cause undesirable side effects...
  42. [42] Item 1A, Risk Factors — We rely completely on third parties, including certain single-source suppliers, to manufacture IBSRELA and XPHOZAH.
  43. [43] Item 1A, Risk Factors — Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement with SLR...
  44. [44] Item 1A, Risk Factors — Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement with SLR...
  45. [45] Item 1A, Risk Factors — Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement with SLR...
  46. [46] Item 1A, Risk Factors — Current and future healthcare reform legislation, regulation or action by the current administration...
  47. [47] Item 1A, Risk Factors — Our success will depend on our ability to obtain, maintain and protect our intellectual property rights.
  48. [48] Item 1A, Risk Factors — We and our collaborators, CROs and other contractors and consultants depend on information technology systems...

Analysis on 5/22/2026